
Figure 1


S-2266 Activity
0
1
2
3
4
5
6
7
0.01
0.1
1
10
100
Soluble Tissue Factor (nM)
+ sTF-3E10 scFv (800 nM)
$K_{D(app)}$ = 2.6 nM
Control
$K_{D(app)}$ = 13 nM
Zero TF Control



S-2266 Activity
4
3.5
3
2.5
2
1.5
0.1
1
10
100
1000
10000
sTF-3E10 (nM)
$K_{D(app)}$ = 65 nM
Zero scFv
Control

Figure 2



A3E10Compl_NDH
A3E10Compl_Fit
Complex
Kd = 33 nM
Data: A3E10Compl_NDH
Model: OneSites
Chi^2 = 315683
N 1.140 ±0.01122
K 3.001E7 ±3.742E6
ΔH -2.857E4 ±406.0
ΔS -80.04
kcal/mole of Injectant
Molar Ratio
A3E10sTF_NDH
A3E10sTF_Fit
Free TF
Kd = 600 nM
Data: A3E10sTF_NDH
Model: OneSites
Chi^2 = 315087
N 0.8781 ±0.01080
K 1.671E6 ±1.705E5
ΔH -2.185E4 ±374.4
ΔS -43.60
kcal/mole of Injectant
Molar Ratio

Figure 3



FXa Activity
20
15
10
5
0
0.0001
0.001
0.01
0.1
1
10
100
1000
scFv-3E10 (nM)
Zero scFv Control
IC50 = 0.44 nM
Zero TF Control

Figure 4



2 fold extension PT (nm)
1600
1200
800
400
0
1.2 uM (17x)
417 nM (6X)
70 nM (1X)
scFv(TF)3e10
TMi456
Fusion

Figure 5



APC activity (mOD/min)
100
75
50
25
0
0
1
2
3
4
5
6
7
[TM or Fusion] nM
TMi456
Fusion

Figure 6




Figure 7



APTT (secs)
160
120
80
40
0
Control
scFv(TF)
TMi456
Fusion
At concentrations for 2 fold extension of PT

Figure 8



% uninhibited control (TEGR)
800
600
400
200
0
scFv(TF)3e10
TMI456
Fusion

Figure 9



R (fusion)
R (LMWH)
R value (TEG)
Relative concentration
300
250
200
150
100
50
0
0
2
4
6
8
10
12
14
16
18

Figure 10



Score
3
2
1
0
Control
scFv(TF)3e10
scFv(TF)3e10-TMi456
*
*
Mortality (%)
80
60
40
20
0
-20
* p<0.05 ZK820822 vs. all other compounds
0.01
0.1
1
10
100
Dose (nmol/kg)

Figure 11